A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

NCT05067140 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

DRUG: ARV-766 Part A&B
DRUG: ARV-766 + Abiraterone Part C&D

Sponsor

Novartis Pharmaceuticals